termios Competitors

AMBOSS is a medical technology company with offices in New York, Berlin, Cologne and Cagliari. Its knowledge platform has fundamentally changed the way medical know-how is acquired and utilized at the point of care. Students use the interactive library and high-yield question bank for general study and exam preparation, while clinicians rely on AMBOSS to make effective clinical decisions guided by evidence-based recommendations. Founded in 2012 by physicians for physicians, the company’s international team has grown to over 400 physicians, scientists and software engineers, all striving to better serve physicians around the world. Today, more than a million healthcare professionals in over 180 countries rely on AMBOSS. Privacy Policy: https://www.amboss.com/us/privacy Terms of Conditions: https://www.amboss.com/us/terms German Datenschutzrichtlinien: https://www.amboss.com/de/de-legal/datenschutz-uebersicht German Impressum: https://www.amboss.com/de/impressum

Kry is Europe’s largest digital healthcare provider, allowing patients to see a doctor, nurse, or psychologist through video consultations within minutes. We’ve delivered 14+ million patient appointments transforming access to high quality care at scale. Above all else, we’re driven by our vision of great healthcare for everyone. Headquartered in Stockholm and backed by some of Europe’s most renowned investors, our employees and 3000+ healthcare professionals are committed to improving the world’s health through innovation, one patient at a time. Through our products, we’re harnessing the power of technology to integrate, primary, urgent and secondary care within digital and physical care settings so patients connect to the right care, at the right time. We work with partners to tailor member journeys and with public health systems to deliver efficient care, at a lower cost. Kry operates in Sweden, UK, France and Norway. To learn more, visit www.kry.se / www.kry.co.uk / www.kry.fr / www.kry.no

Ada is pioneering a new way of patient finding — meeting people at the moment they search for answers and guiding them to the right care faster. Built by doctors and scientists, Ada’s Clinical AI is regulated as a Class IIa medical device in the EU. Our assessments are more than symptom checks — they enable partners to identify underdiagnosed patients, accelerate time-to-diagnosis, and measure real-world outcomes. Pharma organizations use Ada to engage patients earlier in their journey and connect them to the therapies they need. Health systems and insurers leverage Ada to route patients to appropriate care and surface underutilized benefits. With 13 million users worldwide and over 32 million assessments completed, Ada is trusted globally to transform uncertainty into action.